论文部分内容阅读
目的 :观察抗肿瘤药物VM -2 6(替尼泊甙 )治疗颅内恶性肿瘤的疗效。方法 :近 5年来笔者应用VM -2 6+MeC CNU(甲基亚硝脲 )治疗颅内恶性肿瘤患者 69例 ,并对其临床资料和方法进行分析总结。结果 :随访 5 3例 ,其中原发性脑肿瘤 3 9例 ,存活期至少 1年 ,最长超过 5年 ,平均 3年 4个月。14例脑转移瘤存活期至少 8个月 ,最长 6年 ,平均 14个月。结论 :VM -2 6具有低毒性、高脂溶性、分子量小、易通过血脑屏障等特点 ,已渐成为颅内恶性肿瘤的主要化疗药物。
Objective: To observe the efficacy of anti-tumor drug VM -2 6 (teniposide) in the treatment of intracranial malignant tumors. Methods: In the past 5 years, the author applied VM -2 6 + MeC CNU (Methylnitrosourea) to treat 69 cases of intracranial malignant tumor, and analyzed its clinical data and methods. Results: Fifty-three cases were followed up, including 39 primary brain tumors with a survival of at least 1 year and a maximum of 5 years, with an average of 3 years and 4 months. 14 cases of brain metastases survival of at least 8 months, up to 6 years, an average of 14 months. Conclusion: VM -2 6 has low toxicity, high fat solubility, low molecular weight, easy to pass the blood-brain barrier and other characteristics, has become a major intracranial malignant tumor chemotherapy drugs.